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LETTERS TO THE EDITOR 1083reduce IL-33 bioavailability, providing a second mechanism to
reduce IL-33 function in vivo. These results are in accord with
the odds ratio, indicating the variants in IL1RL1 confer protection
against asthma susceptibility and further corroborate other ge-
netic and functional studies implicating a role for the IL-33/
ST2 pathway in asthma pathogenesis.
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Maternal selenium status in pregnancy,
offspring glutathione peroxidase 4 genotype,
and childhood asthma
To the Editor:
Two prospective birth cohort studies have suggested that
prenatal selenium status may play a role in the inception of
childhood asthma. In the Avon Longitudinal Study of Parents and 2014 The Authors. Published by Elsevier, Inc. on behalf of the Academy of Allergy,
Asthma & Immunology. This is an open access article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).Children (ALSPAC), umbilical cord tissue concentration of sele-
nium was negatively associated with risk of wheezing in early
childhood1; in another United Kingdom cohort, maternal and cord
plasma selenium concentrations were negatively associated with
wheezing in the second year of life, but not at 5 years.2 Associa-
tions between biomarkers of prenatal selenium exposure and
asthma and wheezing later in childhood have not been reported.
Glutathione peroxidase (GPX) 4 is a unique membrane-
associated selenium-dependent antioxidant enzyme that can
directly reduce phospholipid hydroperoxides and protect against
oxidative stress in mammalian cells.3 Aside from its antioxidant
role, GPX4 has been implicated in lipoxygenase metabolism,4
which hasmajor relevance to leukotriene synthesis and inflamma-
tory signaling in asthma. Thus, demonstration of an interaction
between selenium status and GPX4 genotype on asthma risk
could strengthen the evidence for a causal role of selenium.
In the ALSPAC birth cohort, we investigated whether higher
maternal blood concentration of selenium in pregnancy is
associated with a lower risk of asthma and wheezing at age 7
years and whether associations are modified by the GPX4 ge-
notype (rs713041). Details of the ALSPAC protocol can be
found at http://www.alspac.bris.ac.uk. Methods for maternal
selenium analysis have been described in detail previously5;
whole blood samples were obtained from 4484 women as early
as possible in pregnancy, and selenium analysis was performed
by the Centers for Disease Control and Prevention, Atlanta,
Georgia, in 2009-2010. After excluding assay failures, sele-
nium measurements were complete for 4287 women. The
mean (interquartile range) of the gestational timing of blood
samples was 11.7 (9-13) weeks (median, 11 weeks; range, 2-
42 weeks). Maternal blood selenium concentrations were log
transformed for analysis. Children were defined as having cur-
rent doctor-diagnosed asthma at 7.5 years if mothers responded
positively to the question ‘‘Has a doctor ever actually said that
your study child has asthma?’’ and positively to questions
about wheezing and/or asthma in the past 12 months at 7.5
years. A single nucleotide polymorphism (SNP) in GPX4
(rs713041, at position 718) was typed by LGC Genomics Ltd
(Hoddesdon, Herts, United Kingdom; www.lgcgenomics.com)
in mothers and children using a competitive allele-specific
PCR system (KASPar). Maternal and child GPX4 genotype fre-
quencies did not deviate from Hardy-Weinberg equilibrium.
All analyses were restricted to white mothers and their
offspring. The median blood selenium concentration was
110.37 mg/L (range, 27.4-324.07 mg/L); the arithmetic mean
was 113.82 6 24.53 mg/L. The 20% centile concentration
was 96 mg/L, which approximates to the whole blood concen-
tration of 100 mg/L needed to saturate glutathione peroxidase
activity in adults in vivo.6 After controlling for confounders,
including gestational timing of maternal blood samples (see
this article’s Online Repository at www.jacionline.org for the
full list), it was found that maternal blood selenium concentra-
tion was not associated with childhood asthma (N 5 2298) or
wheezing (N 5 2326) overall (see Table E1 in this article’s
Online Repository at www.jacionline.org), nor was maternal
or child GPX4 genotype associated with these outcomes (see
Table E2 in this article’s Online Repository at www.
jacionline.org). Table I presents the adjusted associations be-
tween maternal blood selenium concentrations and asthma
and wheezing, stratified by maternal and child GPX4 geno-
types. Maternal genotype did not modify the associations.
TABLE I. Associations between maternal blood selenium concentrations during pregnancy and childhood asthma and wheezing,
stratified by maternal and child GPX4 rs713041 genotype
GPX4 rs713041 genotype N
Adjusted OR (95% CI) per
doubling selenium concentration P value N
Adjusted OR (95% CI) per
doubling selenium concentration P value
Asthma Stratified by maternal genotype Stratified by child genotype
C:C 560 0.51 (0.17-1.54) .23 573 0.92 (0.31-2.74) .88
T:C 852 0.95 (0.41-2.22) .91 877 1.18 (0.50-2.78) .70
T:T 326 0.92 (0.29-2.92) .88 298 0.17 (0.04-0.72) .02
P for interaction* .64 .068
Wheezing Stratified by maternal genotype Stratified by child genotype
C:C 567 0.74 (0.24-2.27) .60 577 0.69 (0.26-1.86) .46
T:C 865 1.41 (0.57-3.45) .46 893 1.99 (0.81-4.93) .13
T:T 329 1.14 (0.35-3.66) .83 302 0.16 (0.04-0.66) .01
P for interaction* .68 .011
OR, Odds ratio.
*Testing difference in selenium associations according to genotype.
FIG 1. Odds ratio for asthma, comparing children of mothers in the bottom
quintile for blood selenium concentration with children of mothers in the
top 4 quintiles, and stratifying by child GPX4 rs713041 genotype.
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selenium status and child GPX4 genotype on asthma (P inter-
action .068) and wheezing (P interaction .011), with an odds
reduction of 83% to 84% per doubling increase in blood sele-
nium concentration in children who were homozygous for the
minor T allele of rs713041; maternal blood selenium concen-
tration was not associated with these outcomes in children car-
rying the C allele. Similarly, children of mothers below the
20th centile for blood selenium concentration were more likely
to have asthma than were children of mothers with higher
blood selenium concentration if they were homozygous for
the T allele of rs713041 (odds ratio, 2.21; 95% CI, 0.98-4.99;
P 5 .057), but not if they were carrying the C allele
(P interaction .18) (Fig 1). The main findings were unchanged
when we carried out 2 sensitivity analyses: first, excluding 3
mother-child pairs with outlying maternal blood selenium
values (>300 mg/L); second, after controlling for 10 variables
derived by principal-components analysis from the ALSPAC
genomewide association study data to address possible residual
confounding by population substructure.
In this population-based birth cohort study, we have found a
novel, and plausible, interaction between maternal blood sele-
nium concentration in pregnancy and child GPX4 genotype(rs713041) on the risk of asthma and wheezing at age 7 years.
Our data indicate that lowmaternal blood selenium concentration
increases the risk and higher blood selenium concentration re-
duces the risk but only in genetically susceptible children,
namely, those who are homozygous for the minor T allele of
GPX4. Villette et al4 proposed that the rs713041 SNP in the 39 un-
translated region of GPX4 may influence how efficiently seleno-
cysteine is incorporated into GPX4, leading to altered GPX4
synthesis in response to variations in selenium supply.4 There is
other evidence confirming that T/C variation (rs713041) has
functional consequences,7 including a study showing that in
individuals with the GPX4 (rs713041) TT genotype, oxidative
stress decreased as in vivo selenium concentrations Furthermore,
in vitro, selenium is necessary for the maximum expression of
GPX4 in human lung epithelial cells.9 We therefore propose
that low maternal blood selenium concentration leads to subopti-
mal GPX4 activity and impaired antioxidant defenses against
oxidative stress in fetal airway epithelium, leading to epithelial
damage, which, in turn, contributes to the pathogenesis of asthma.
Alternatively, prenatal selenium status might influence the devel-
opment of asthma through the involvement of GPX4 in lipoxyge-
nase metabolism.4 However, because we cannot exclude the
possibility that the main findings have arisen through type 1 error,
replication of the interaction we observed is needed in another
birth cohort of sufficient size.
Our findings suggest that in a susceptible subgroup of mother-
child pairs in the population, namely, pregnant women with
suboptimal selenium status and offspring with the homozygous
minor variant of GPX4 rs71304, there may be potential to reduce
the incidence of childhood asthma through selenium supplemen-
tation in pregnancy.Whether primary prevention of asthma can be
achieved in this way can be determined only through a clinical
trial; the efficacy of such a trial is likely to be maximized by
adopting a stratified approach.
We are extremely grateful to all the families who took part in this study, to
themidwives for their help in recruiting them, and to thewholeALSPAC team,
which includes interviewers, computer and laboratory technicians, clerical
workers, research scientists, volunteers, managers, receptionists, and nurses.
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fractures in adults: A US population-based
study
To the Editor:
Patients with eczema have multiple potential risk factors for
decreased bone mineral density (BMD), including using large
quantities of topical corticosteroids, systemic corticosteroids, and
chronic inflammation. Furthermore, eczema is associated with
distraction from itch, mental health comorbidities, and sleep
disturbance,1 all of which predispose to fractures and other
injuries.2,3 However, previous studies examining BMD in adults
with eczema found conflicting results4-6 and their risk of fractures
has not been fully explored. In the present study, we analyzed datafrom a large-scale US-population–based study to assess the
burden of fractures in adult eczema.
We used the 2005-2006 National Health and Nutrition Exam-
ination Survey. Household surveys were performed in-person in
English and Spanish, as well as health examinations, blood
collection, and dual-energy x-ray absorptiometry (DEXA) in
mobile examination centers. Survey results were weighted to
represent the population of US adults using data from the US
Census Bureau. Approval by the Northwestern University
institutional review board was waived.
Sociodemographic characteristics included age, sex, race,
education level, and household income. Lifetime history of
doctor-diagnosed osteoporosis and prednisone/cortisone use
daily for at least 30 days were assessed. Daily tobacco and
alcohol consumption habits were assessed. History of eczemawas
assessed by a positive response to the question, ‘‘Has a doctor or
other health professional ever told (you/sample person) that (you
have/sample person has) eczema?’’ To improve the specificity of
self-reported eczema, subjects who reported a health care pro-
vider diagnosis of psoriasis were excluded from analyses. History
of fractures was determined by asking ‘‘Has a doctor ever told
(you/sample person) that (you/s/he) had broken or fractured .
(your/his/her) hip?’’, ‘‘. (your/his/her) spine?’’, ‘‘. (your/his/
her) wrist?’’, ‘‘. any other bone after (you were/s/he was) 20
years of age?’’ A composite binary variable was created on the
basis of the above responses.
The BMD (g/cm2) of the hip and spine was measured by using
DEXA on all eligible participants. Total femur, femoral neck,
trochanter, and spine scans were performed with a Hologic
QDR-4500A fan-beam densitometer (Hologic, Inc, Bedford,
Mass) as previously described.7 BMD-for-age, sex, and race/
ethnicity t scores were also determined on the basis of National
Health and Nutrition Examination Survey reference standards.8
Physical examination was performed,9 body mass index was
calculated, and blood samples were collected.
Bivariate and multivariate analyses were performed with
SURVEY procedures in SAS (version 9.4; SAS Institute, Cary,
NC). Bivariate associations between eczema, fracture, metabolic
factors, and sociodemographic variables were tested via logistic
regression models. Bivariate associations between eczema and
BMD were tested via linear regression models. Complete data
analysis was performed. Two-way interaction terms between
eczema and age, sex, race, and household income were
tested. Interactions were included in final models if P was less
than .01 and modification of estimates was more than 20%.
A 2-sided P value of less than .05 was taken to indicate statistical
significance.
A total of 4972 people aged 20 to 85 years were included in this
analysis. The prevalence (95% CI) of eczema was 7.4% (6.5% to
8.3%), of which 24.7% (18.8% to 30.5%) also had a lifetime
history of asthma. The prevalence of any fracture was 32.3%
(30.7% to 33.9%). Hip or spine fractures were described in 3.9%
(3.3% to 4.6%), whereas 30.6% (29.0% to 32.2%) reported
having ‘‘other’’ fractures. Associations with the prevalence of
eczema and fractures are presented in Table E1 in this article’s
Online Repository at www.jacionline.org. Adult eczema was
not associated with 25-OH vitamin D, calcium, parathyroid hor-
mone, alkaline phosphatase, albumin, lactate dehydrogenase,
C-reactive protein, or peripheral white blood cell counts
compared with those without AD (see Table E2 in this article’s
Online Repository at www.jacionline.org).
CONFOUNDERS
In multivariate analyses, we controlled for the following
potential confounders: maternal factors during pregnancy (smok-
ing, infections, anxiety score, and use of antibiotics, alcohol, and
paracetamol); other maternal factors (educational level, housing
tenure, financial difficulties, body mass index, age, parity, and
history of asthma, eczema, rhinoconjunctivitis, and migraine);
sex of child, season of birth, multiple pregnancy, gestational age,
birth weight, head circumference, and birth length; and postnatal
factors (breast-feeding, day care, pets, damp/mold, environmental
tobacco smoke exposure, antibiotic and paracetamol use in
infancy, number of younger siblings, and body mass index at
age 7 years). We also controlled for the gestational timing of
maternal blood samples because whole blood selenium concen-
trations are known to decline as pregnancy progresses.E1
STATISTICAL ANALYSIS
To test for interaction, we included the genotype and selenium
variables, as well as a Genotype 3 Selenium interaction term, in
the regression models.
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TABLE E1. Associations between maternal blood selenium
concentrations during pregnancy and childhood asthma and
wheezing
Disease
Selenium
concentration (mg/L)
Unadjusted
OR (95% CI)
Adjusted OR
(95% CI)
Asthma
(N 5 2298)
Q1 (<_96) 1.0 1.0
Q2 (96-105.74) 0.77 (0.52-1.14) 0.82 (0.54-1.26)
Q3 (105.8-115.47) 0.61 (0.40-0.92) 0.76 (0.49-1.18)
Q4 (115.5-128.7) 0.73 (0.49-1.08) 0.85 (0.55-1.31)
Q5 (128.8-324.07) 0.72 (0.48-1.07) 0.83 (0.53-1.30)
Per doubling 0.66 (0.42-1.04) 0.74 (0.45-1.21)
P value for
trend 5 .07
P value for
trend 5 .24
Wheezing
(N 5 2326)
Q1 (<_96) 1.0 1.0
Q2 (96-105.74) 0.92 (0.60-1.40) 0.97 (0.61-1.54)
Q3 (105.8-115.47) 0.77 (0.50-1.20) 0.96 (0.59-1.54)
Q4 (115.5-128.7) 1.05 (0.70-1.59) 1.16 (0.73-1.84)
Q5 (128.8-324.07) 0.95 (0.62-1.45) 1.07 (0.66-1.72)
Per doubling 0.84 (0.52-1.33) 0.87 (0.52-1.45)
P value for
trend 5 .45
P value for
trend 5 .59
OR, Odds ratio.
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TABLE E2. Association between maternal and child GPX4
rs713041 genotype and childhood asthma and wheezing
Disease
Maternal GPX4
rs713041 genotype OR (95% CI)
Asthma (N 5 1738) N
560 C:C 1.0
852 T:C 0.90 (0.64-1.25)
326 T:T 1.29 (0.87-1.93)
Per allele 1.11 (0.91-1.37)
Wheezing (N 5 1761) N
567 C:C 1.0
865 T:C 0.83 (0.59-1.19)
329 T:T 1.28 (0.85-1.94)
Per allele 1.10 (0.89-1.37)
Disease
Child GPX4
rs713041
genotype OR (95% CI)
Asthma (N 5 1748) N
573 C:C 1.0
877 T:C 1.23 (0.88-1.73)
298 T:T 1.24 (0.80-1.94)
Per allele 1.13 (0.91-1.40)
Wheezing (N 5 1772) N
577 C:C 1.0
893 T:C 0.88 (0.63-1.24)
302 T:T 1.10 (0.71-1.71)
Per allele 1.02 (0.82-1.28)
OR, Odds ratio.
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